Emerging adult age status predicts poor buprenorphine treatment retention
Emerging adult age status predicts poor buprenorphine treatment retention
复制标题
DOI：
10.1016/j.jsat.2014.04.006
复制
发表时间：
2014-09-01
影响因子：
3.9
通讯作者：
Albanese, Mark J.
中科院分区：
文献类型：
--
作者：
Schuman-Olivier, Zev;Weiss, Roger D.;Albanese, Mark J.
新成人（18-25岁）在药物使用障碍治疗中的保留率往往很低。丁丙诺啡通常可以提高阿片类药物依赖者的治疗保留率。在这项研究中，我们检查了合作护理丁丙诺啡治疗计划的记录，以比较新兴成年人与老年人的治疗保留率。受试者为294名成年人，其中71名（24%）年龄在18-25岁之间，随后接受丁丙诺啡治疗、护理管理和强化门诊计划，随后每周接受心理社会治疗。与老年人相比，新兴成年人在3个月（56%对78%）和12个月（17%对45%）时的治疗率显著较低，并且更有可能对非法阿片类药物检测呈阳性，复发或退出治疗。需要进一步研究与新兴成人中丁丙诺啡治疗保留相关的因素，以改善该组的治疗和长期结局。(C)2014年爱思唯尔公司All rights reserved.
Emerging adults (18-25 years old) are often poorly retained in substance use disorder treatment. Office-based buprenorphine often enhances treatment retention among people with opioid dependence. In this study, we examined the records of a collaborative care buprenorphine treatment program to compare the treatment retention rates of emerging adults versus older adults. Subjects were 294 adults, 71(24%) aged 18-25, followed in treatment with buprenorphine, nurse care management, and an intensive outpatient program followed by weekly psychosocial treatment. Compared to older adults, emerging adults remained in treatment at a significantly lower rate at 3 months (56% versus 78%) and 12 months (17% versus 45%), and were significantly more likely to test positive for illicit opioids, relapse, or drop out of treatment. Further research into factors associated with buprenorphine treatment retention among emerging adults is needed to improve treatment and long-term outcomes in this group. (C) 2014 Elsevier Inc. All rights reserved.